Sarepta Therapeutics Provides Generous Grants to Boost Nasdaq Listing and Advance Innovation

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has recently taken a major step in its commitment to precision genetic medicine for rare diseases, granting generous equity awards to 19 new employees as a material inducement to employment. Approved by the Compensation Committee of the Board of Directors and in accordance with Nasdaq Listing Rule 5635(c)(4), these awards are a significant reward for the individuals hired in February 2023 and demonstrate Sarepta’s commitment to its mission.

On February 28, 2023, Sarepta gave its employees a generous reward: the option to purchase 20,100 shares of common stock at the closing price of $122.13 per share. This reward was accompanied by 11,000 restricted stock units, adding to the already impressive package. Each employee’s option will vest in increments over four years, with one-fourth of the shares vesting on the one-year anniversary of the Grant Date, and the remaining shares vesting monthly until the fourth anniversary of the Grant Date. To receive these rewards, each employee must remain employed with Sarepta throughout the vesting period.

Every year on the anniversary of the Grant Date, a quarter of the RSUs will vest for each employee, with the full RSUs vested after four years of continued employment with Sarepta.

About Sarepta Therapeutics

Sarepta is on a mission to revolutionize the way rare diseases are treated. Our incredible team of scientists is working hard to develop precision genetic medicine to help those living with devastating conditions like Duchenne muscular dystrophy and limb-girdle muscular dystrophy. We have over 40 programs in development, all powered by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. With our cutting-edge approaches, we are determined to save lives and create brighter futures.

Leave a Comment